Adalvo is pleased to announce a new collaboration with Stendhal, a Mexican pharmaceutical company that provides innovative therapies to improve the quality of life of patients, with presence in Mexico and Latin America. The licensing agreement covers a complex antibiotic niche product for the treatment of acute bacterial skin and skin structure infections (ABSSI), which will be available in Mexico and Colombia.
This collaboration is integral to Adalvo's commitment to expanding its presence in LATAM and improving patient access to essential medications through close collaboration with its partners.
"We are thrilled to have finalized this licensing agreement with Stendhal. This agreement marks a significant milestone in our efforts to expand our commercial reach in LATAM, and we are excited to work closely with Stendhal in strengthening our partnership. We believe that this collaboration will enable us to provide high-quality medicines to patients in need and contribute to improving healthcare outcomes in the region.
Innovation is one of our pillars, and we are always looking for new technologies that meet the needs of patients, as stated in our motto: "Taking care of life". Undoubtedly, this alliance, and the product that Stendhal will be launching as a result of it, will provide the physicians and patients with a safe and convenient alternative for the treatment of ABSSI, particularly the complicated cases, in many cases obviating the need for the patients to be hospitalized to receive their treatments.